Stock Code: 002393 Stock Abbreviation: Life Pharmaceutical Announcement No.: 2026-017 Tianjin Life Pharmaceutical Co., Ltd. Announcement on the Proposal for Profit Distribution and Capital Reserve Transfer to Share Capital in 2025
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
I. Deliberation Procedures The Company held the Fourth Meeting of the Eighth Board of Directors on March 24, 2026, which reviewed and approved the "Proposal for Profit Distribution and Capital Reserve Transfer to Share Capital in 2025." This proposal needs to be submitted to the Company's 2025 Annual General Meeting for deliberation.
II. Basic情况 of the 2025 Profit Distribution Proposal and Capital Reserve Transfer to Share Capital According to the audit by Dahua Certified Public Accountants, Life Pharmaceutical's parent company achieved a net profit of RMB 95,633,147.48 in 2025. In accordance with the provisions of the "Articles of Association," 10% of the net profit realized by the parent company in 2025, amounting to RMB 9,563,314.75, was allocated to the statutory surplus reserve. Undistributed profits from previous years were RMB 1,267,378,547.78. The cash dividends distributed in the 2024 distribution plan and the first three quarters of the 2025 distribution plan totaled RMB 166,758,815.55. The profit available for distribution is RMB 1,186,689,564.96.